Allergan Adds Device To Glaucoma Portfolio
This article was originally published in The Gray Sheet
Executive Summary
The pharmaceutical firm is entering the highly touted micro-invasive glaucoma surgery space with an acquisition of AqueSys, adding a device to its established portfolio of glaucoma drugs.
You may also be interested in...
FDA Leaps To Draft Glaucoma Device Guidance
FDA issued a "leap frog" draft guidance for minimally invasive glaucoma surgery (MIGS) devices based on strong interest in the nascent field from manufacturers. The recommendations under the guidance reflect discussion during a 2014 stakeholder workshop.
Two Companies, One Owner; US FDA Sends Warning Letters To Same Address For Similar Issues
Two Massachusetts-based infusion pump manufacturers with the same founder and CEO received warning letters from the US FDA for similar violations.
Swiss Finally Beat EMA On New Drug Approval Times
More rolling reviews, a reduction in review rounds, and a rise in applications through two international regulatory collaboration initiatives were among the factors behind a reduction in new drug authorization times in Switzerland last year. However, “submission gaps” versus other regulators remain a problem.